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Abstract
Background: The effect of L-arginine and L-citrulline on blood pressure and right ventricu-
lar function in heart failure patients with preserved ejection fraction (HFpEF) is unknown.
We have therefore evaluated, in a randomized clinical trial, the effect of these aminoacids in
chronic outstanding and stable patients with HFpEF.
Methods and results: All patients underwent an echocardiogram and radioisotopic ven-
triculography rest/exercise, and were randomized in a consecutive manner to the L-arginine
group (n = 15; 8 g/day); and the citrulline malate group (n = 15; 3 g/day). The duration of
follow-up was two months. The principal echocardiographic finding was a statistically signifi-
cant decrease in pulmonary artery pressure in the L-arginine (56.3 ± 10 vs 44 ± 16.5 mm Hg,
p < 0.05) and the citrulline (56.67 ± 7.96 vs 47.67 ± 8.59 mm Hg, p < 0.05) groups.
Duration on treadmill and right ventricular ejection fraction post exercise increased, while
diastolic and systolic artery pressure decreased significantly in both groups. There were no
other statistically significant differences between the groups.
Conclusions: Administration of L-arginine and citrulline to patients with HFpEF improved
right ventricular function by increasing right ventricular ejection fraction, and probably de-
creasing systolic pulmonary artery pressure. (Cardiol J 2010; 17, 6: 612–618)
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Introduction
Heart failure (HF) is a clinical syndrome of
considerable morbidity and mortality. The physio-
pathology of HF results from the interaction of
multiple deleterious mechanisms that include ven-
tricular remodeling, over-activation of the neuro-
hormonal system and cytokines as well as endo-
thelial dysfunction. Endothelial dysfunction is one
of the primary factors in a number of other patho-
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logical conditions often seen in these patients such
as systemic hypertension, diabetes mellitus, and
atherosclerosis [1].
Left ventricular ejection fraction (LVEF) is
preserved in 30 to 50% of HF cases [2], but their
prognosis is as poor as those with depressed systo-
lic function. Systemic hypertension, coronary artery
disease and senility are the commonest causes of this
type of dysfunction. Chronic systemic hypertension
augments wall stress and induces parallel hypertro-
phy of the sarcomeres, which increases wall thick-
ness. Muscular hypertrophy and increase in the
thickness of the collagen matrix prevents progres-
sive dilatation and maintains stable wall stress, but
it also diminishes distensibility [3].
Pulmonary arterial hypertension (PAH) has
recently been identified in heart failure patients
with preserved ejection fraction (HFpEF) [4]. The
prevalence reaches 83% [5] and persists after cor-
recting for pulmonary capillary wedge pressure.
This suggests that apart from post-capillary pulmo-
nary venous congestion, a pre-capillary component
contributes to higher pulmonary artery pressure in
patients with preserved ejection fraction and is an
important factor in an adverse prognosis [5].
Rector et al. [6] demonstrated in HF patients
(LVEF 18 ± 5%) that administration of oral L-argi-
nine (5.6 to 12.6 g/d.) over the course of six weeks
significantly improves limb blood flow during exer-
cise and arterial compliance; they also found that
circulating levels of endothelin were reduced by
L-arginine. Plasma endothelin has a strong relationship
with mean pulmonary vascular resistance.  In another
study, patients with HF (LVEF 19 ± 9%) were sup-
plemented with 8 g/day L-arginine. After four weeks,
the authors found an 8.8% improvement in acetylcho-
line-mediated vasodilation of the radial artery [7].
L-arginine is a basic, semi-essential amino acid
formed from citrulline and ornithine that participates
as an intermediary compound in the urea cycle. It is
also the precursor for the endogenous synthesis of
nitric oxide (NO) due to the activity of nitric oxide
synthase (NOS), which releases L-citrulline as
a byproduct [8].
L-citrulline is an alpha amino acid that is me-
tabolized in the vascular endothelium, renal and
other cells to L-arginine. Oral L-citrulline increas-
es the blood concentration of L-arginine more ef-
fectively than oral L-arginine itself, because it un-
dergoes neither intestinal nor hepatic metabolism.
Since it is not a substrate for arginase, it does not
induce the expression or activate the enzyme. This
makes citrulline a promising treatment in cardio-
vascular disease involving L-arginine deficiency,
bioavailability of NO and endothelial dysfunction. In-
creases in peak L-arginine concentrations of 227%
from basal levels four hours after administration
were obtained when L-citrulline was given at a dose
of 3.8 g/m body surface area. The same dose of
L-arginine increased circulating levels by only 90%
[9, 10].
L-arginine is the sole substrate for NOS and
thus is essential for NO production. It is estimated
that the average diet is borderline in arginine con-
tent, and circulating levels can be reduced by ad-
ministration of arginine-deficient protein [11, 12],
by pregnancy [13–17], aging, or stress [18].
The administration of arginine and citrulline
may play a fundamental role in patients in heart fail-
ure by preventing endothelial dysfunction. Howev-
er, no study has focused on patients in heart failure
with preserved ejection fraction and right ventric-
ular dysfunction. Likewise, to our knowledge, the
clinical outcome of oral administration of L-argini-
ne and L-citrulline on patients with HFpEF has not
been reported.
The aim of the present study was to evaluate
the effects of oral supplementation with L-arginine
or L-citrulline malate on arterial pressure and right
ventricular function in patients with HFpEF.
Methods
Study population
This controlled clinical study included ambu-
latory patients who came to the Heart Failure Cli-
nic of the Instituto Nacional de Ciencias Médicas
y Nutrición “Salvador Zubirán” between January
and December  2008. Patients were recruited if
they were men or non-pregnant women more than
18 years of age with a confirmed diagnosis of heart
failure with preserved ejection fraction, stable and
in New York Heart Association functional classes
I to III. Candidates were excluded if they present-
ed with lung disease, ischemia treatable by revas-
cularization, myocardial infarction, unstable angi-
na or a history of myocardial revascularization
(percutaneous transluminal coronary angioplasty
or aorto-coronary by-pass grafts), cerebrovascu-
lar events during the previous three months, dys-
functional prosthetic heart valve, obstructive or
non-obstructive cardiomyopathy, uncorrected con-
genital heart disease, active myocarditis, history
of resuscitation from sudden death, or severe ar-
rhythmias.
Heart failure was established by characteristic
signs and symptoms as well as echocardiographic and
radioisotopic ventriculography findings. Preserved
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ejection fraction was defined by LVEF ≥ 45%, fractio-
nal shortening ≥ 28%, left atrial diameter > 45 mm,
ventricular septal thickness > 12 mm, posterior wall
thickness > 12 mm, and characteristic pattern of
transmitral Doppler flow (slow, inverted, pseudo-
normal or restrictive) [19]. Right ventricular dysfunc-
tion was defined as ejection fraction £ 35% measured
by radioisotopic ventriculography [20, 21].
All patients were on standard HF therapy (diu-
retics, ACE inhibitors, angiotensin II antagonists,
aldosterone receptor blockers, beta-adrenergic re-
ceptor blockers and digitalis (in patients with atrial
fibrillation).
After baseline measurements, patients were
randomly assigned to one of the following groups:
1) oral L-arginine supplementation (n = 15) who re-
ceived 8 g per day of L-arginine powder split into
two doses of 4 g; or 2) oral L-citrulline (n = 15) who
received 3 g per day of L-citrulline malate powder
in two doses of 1.5 g. Randomization was performed
using a sequential series of numbered sealed en-
velopes containing computer-generated random as-
signments. A copy of the randomization sequence
was kept in a locked cabinet away from the study
personnel. Randomization envelopes were opened
by a third party who informed the patients. Patients,
investigators, and study personnel were blinded to
the treatment group allocation. Study products were
packaged identically and indistinguishable from one
another.
Supplements were provided as weighed daily
amounts to be taken as a drink mixed with juice or
water throughout the day, during the two-month
treatment period. Compliance was evaluated using
the supplement consumption records kept daily by
patients, and by collecting the empty containers.
The study was approved by the institutional
Ethics Committee of Biomedical Research in Hu-
mans of the Instituto Nacional de Ciencias Médi-
cas y Nutrición “Salvador Zubirán”, and all partici-
pants gave written informed consent.
Measurements
All participants underwent multi-stage exer-
cise testing according the modified Bruce protocol
to obtain functional capacity (METs), blood pres-
sure and heart rate at rest and after exercise. Heart
rate, systolic and diastolic blood pressures were
recorded by cuff when the subject was standing
immediately before testing and during the last
minute of the last exercise stage. Subjects exer-
cised until reaching an age-specific target heart rate
or developing symptoms necessitating termination
of the test or high blood pressure.
Right ventricular function was evaluated by
radioisotopic ventriculography. The procedure was
performed at rest in the supine position using an in
vivo red blood cell labeling with 99mTc by standard
methods [22]. The patients were to have fasted for
four hours prior to the study and refrained from
caffeine for 24 hours. They were injected with
40 mg of stannous pyrophosphate in 1.5 mL saline.
Ten minutes later, the patients were positioned on
the bed of the camera with the detector in the right
anterior oblique position. A rapid bolus of 20 mCi
technetium-99m pertechnetate was given intrave-
nously as the list mode acquisition was initiated.
Following the first pass study, and after time for
equilibration in the blood volume, a standard gated
cardiac blood pool study was acquired in the left
anterior oblique (LAO) and left lateral projections.
The R to R interval was divided into 16 frames not
greater than 0.04 s in length. Multi-gated acquisi-
tion was recorded for 900 s in a 64 x 64 matrix.
Quantification was performed on the LAO view.
Processing and measurements were made accor-
ding to the Nuclear Cardiology Society recommen-
dations.
Systolic pulmonary artery pressure (SPAP)
was measured by evaluation of maximal velocity of
tricuspid regurgitation (TR) according to Europe-
an guidelines for the diagnosis and treatment of
pulmonary hypertension (PH), considering echocar-
diographic diagnosis of PH ‘likely’ when TR is
> 3.4 m/s (or SPAP > 50 mm Hg) and ‘possible’
when TR is between 2.9–3.4 m/s (or SPAP is be-
tween 35–40 m Hg, with or without additional
echocardiographic signs, or when TR is £ 2.8 m/s
(or £ SPAP is £ 36 mm Hg) with additional varia-
bles suggestive of PH (right ventricular hypertro-
phy or dilation) [23].
The cardiologist who performed the echocar-
diograms and radioventriculography did not have
access to patients’ information.
Statistical analysis
Continuous variables were expressed as mean
± standard deviation (SD), and categorical variables
as absolute and relative frequency. For comparisons
between the groups c2 or Fisher’s exact test for cate-
gorical variables and Mann-Whitney U test for
continuous variables were used. To compare the
changes from baseline to two months, the Wilco-
xon signed rank test was used. A p value of
< 0.05 was considered statistically significant. All
analyses were performed using a commercially
available package (SPSS for Windows, version 10.0,
SPSS Inc., Chicago, Illinois, USA).
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Results
Of the 30 patients included in the study, three
were eliminated. In the arginine group; one patient
presented with gastrointestinal distress and another
was hospitalized for non-cardiovascular causes. One
patient in the citrulline group underwent surgery
for a non-cardiovascular cause. Other than the pa-
tients with gastrointestinal symptoms, no adverse
effects were observed.
The baseline characteristics of the study
groups are shown in Table 1. Non-significant dif-
ferences were observed among the groups. In both
groups, there were patients using digitalis because
they have atrial fibrillation. Basal echocardiography
and radioisotopic ventriculography results also re-
vealed no significant differences.
After two months of follow-up, the principal
echocardiographic finding was a statistically signif-
icant decrease in systolic pulmonary artery pres-
sure in both groups (Table 2).
Also, duration on the treadmill and right ven-
tricular ejection fraction during the stress increased
significantly in the arginine and citrulline groups.
Furthermore, in the citrulline group there was
a significative increase in right ventricular ejection
fraction after the stress test (Table 2).
Both systolic and diastolic blood pressure de-
creased significantly in the two groups, but the decrease
in systolic blood pressure was greater in the arginine
group but was not statistically significant (Fig. 1).
Discussion
The present controlled clinical study is one of
the first to report an improvement in pulmonary
artery pressure and right ventricular ejection frac-
tion after two months of oral supplementation with
L-arginine or citrulline in patients with HFpEF and
right ventricular dysfunction. This outcome is note-
worthy because HFpEF and pulmonary arterial
hypertension frequently co-exist. Apart from in-
creased post-capillary pulmonary pressure, there is
an additional pre-capillary pulmonary factor in which
the tone and/or pulmonary vascular remodeling can
contribute to increased pulmonary artery pressure.
Table 1. Baseline clinical characteristics of the study population.
Variables Arginine group (n = 15) Citrulline group (n = 15)
Age (years) 63 ± 14 66 ± 10
Female 7 (46.7%) 6 (40%)
Male 8 (53.3%) 9 (60%)
NYHA:
I 8 (53%) 4 (26%)
II 6 (40%) 11 (73%)
III 1 (6%) 0 (0%)
Ischemic heart disease 6 (40%) 7 (46%)
Diabetes mellitus 8 (53%) 8 (53%)
Obesity 8 (53%) 9 (60%)
Dyslipidemia 4 (27%) 5 (33%)
Systemic hypertension 14 (93%) 13 (87%)
Hypothyroidism 4 (27%) 6 (40%)
Atrial fibrillation 3 (20%) 3 (20%)
Pulmonary arterial hypertension 10 (71%) 13 (87%)
ACEI 2 (13%) 6 (40%)
ARA 12 (80%) 9 (60%)
Aspirin 6 (40%) 5 (33%)
Thiazide diuretic 6 (40%) 3 (20%)
Loop diuretic 4 (27%) 5 (33%)
Nitrates 2 (13%) 4 (26.7%)
Spironolactone 13 (87%) 10 (66.7%)
Betablockers 12 (80%) 12 (80%)
Digitalis 5 (33%) 3 (20%)
Data is presented as mean ± standard deviation or n (%); ACEI — angiotensin converting enzyme inhibitor; ARA — angiotensin receptor antagonist
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Lam et al. [5] recently suggested that the severity
of the pulmonary arterial hypertension could serve
to identify patients with HFpEF with excellent dia-
gnostic accuracy. In these cases, use of amino acid
precursors to NO could be a therapeutic option.
Systolic pulmonary artery pressure was mea-
sured by evaluation of maximal velocity of tricus-
pid regurgitation. This technique is widely validat-
ed, but its precision is debatable [23]. It is known
that using indirect measurements of SPAP by
echocardiography means that it is not possible to
assess total pulmonary resistance, and therefore
whether the decrease of pulmonary artery pressure
is due to a decline in precapillary resistance or to
a decrease of pulmonary capillary wedge pressure
(PCWP). This is a parameter used to quantify left
ventricular filling pressures and help to discrimi-
nate between PH and pulmonary venous hyperten-
sion (i.e. secondary to left ventricular disease; the
cut-off used is 15 mm) [24].
Patients with PH typically have Doppler mitral
inflow patterns of impaired relaxation (grade I dia-
stolic dysfunction), with normal E’ waves on DTI
and E/E’ septal ratios < 10, despite high SPAP. In
contrast, patients with  high SPAP secondary to
elevated atrial pressures and left-heart disease tend
to have pulsed-wave Doppler mitral inflow patterns
of grade II or III, with increased E/E’ ratios [23]. At
the moment, there is no conclusive data that sup-
ports the use of usual indexes for monitoring clini-
cal evolution or treatment response in patents with
PH. But, SPAP can frequently be estimated using
the TR method. However, it is very important to
consider the contribution of left ventricular end-di-
astolic pressures in the pulmonary hemodynamics
of a specific patient, because left-heart disease is
probably the most frequent cause of pulmonary hy-
pertension. In these cases, mild to moderate increas-
es in pulmonary pressure and pulmonary wedge pres-
sure are found, and PVR is generally normal [23].
The impact of arginine treatment on the pul-
monary hemodynamics of adults with pulmonary
vascular disease has been mixed [25, 26]. Howev-
er, chronic arginine supplementation could improve
lung circulation in patients with pulmonary arterial
hypertension. Short-term administration of L-argi-
nine (500 mg/kg infused over 30 min) in ten sub-
jects with PAH resulted in a reduction in pulmo-
nary artery pressure [25]. Infusion of L-arginine has
Table 2. Echocardiographic and ventriculographic results of study groups at baseline and after two
months.
Variables Baseline Two-month follow-up
Arginine group Citrulline group Arginine group Citrulline group
(n = 13) (n = 14) (n = 13)  (n = 14)
Echocardiogram
LVSD [mm] 31 ± 5.5 30 ± 5 29 ± 6 29 ± 5
RVDD [mm] 41 ± 7 42 ± 6 38 ± 6 40 ± 7
SPAP [mm Hg] 56 ± 10 57 ± 8 44 ± 16* 48 ± 9*
Radioisotopic ventriculography
Duration on treadmill [min] 7 ± 6 6 ± 3 8 ± 4* 6 ± 3*
LVEF (%): resting vs stress 33 ± 14 vs 41 ± 14 vs 38 ± 12 vs 39 ± 16 vs
37 ± 14 37 ± 14  38 ± 13 39 ± 17
RVEF (%): resting vs stress 25 ± 9 vs 28 ± 13 vs 26 ± 9 vs 27 ± 7 vs
26 ± 12 26 ± 11  34 ± 15* 33 ± 15*
*Denotes p < 0.05 vs baseline; data is presented as mean ± standard deviation; LVSD — left ventricular systolic diameter; RVDD — right ventricular
diastolic diameter; SPAP — systolic pulmonary artery pressure;  LVEF — left ventricular ejection fraction; RVEF — right ventricular ejection fraction
Figure 1. Percentage change in blood pressure in study
groups after two-month follow-up; SBP — systolic
blood pressure; DBP — diastolic blood pressure.
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also resulted in markedly increased plasma levels
of L-arginine as well as a rise in plasma L-citrul-
line. The peak plasma level of L-citrulline had a sig-
nificant correlation with reduction in pulmonary
artery pressure, possibly because of vasodilatation
mediated by NOS metabolism of exogenous L-argi-
nine and increased NO production.
Arginine deficiency has been shown to accom-
pany persistent PH of the newborn (PPHN) [27],
and acute L-arginine infusion (500 mg/kg over 30 min)
of infants with PPHN was associated with a rise in
PaO2 over the five hour period following infusion [28].
Other studies demonstrated that chronic administra-
tion of L-arginine ameliorated chronic PH and vascu-
lar remodeling induced in rats by either chronic hy-
poxia or monocrotaline injection [29].
Consistent with other studies [30, 31] we ob-
served a statistically significant decrease in system-
ic blood pressure and systolic pulmonary artery
pressure with oral arginine and citrulline.
A study published by Nagaya et al. [32] sug-
gests that oral supplementation with L-arginine has
beneficial effects on hemodynamic values and ex-
ercise capacity in patients with PAH. Acute hemo-
dynamic responses to oral L-arginine (0.5 g/10 kg
b.w. weight) compared to placebo were examined
in 19 patients with PAH. Cardiopulmonary exercise
tests were performed to measure peak oxygen con-
sumption and the ventilatory response to carbon
dioxide production before and after one week of
treatment with L-arginine (1.5 g/10 kg b.w. per day)
or placebo. Oral supplementation with L-citrulline
significantly increased plasma L-arginine, which in-
dicated enhanced NO production.
As Rector et al. [6] demonstrated, limb blood
flow during exercise and arterial compliance was
associated with circulating levels of endothelin and
was reduced by L-arginine. Plasma endothelin has
a strong relationship with mean pulmonary vascu-
lar resistance and it could be a rational hypothesis
to explain our findings in the pulmonary pressure
reduction. In our cases, the fact that neither NO nor
endothelin were measured means a limitation to our
preliminary results. However, their dynamic effect
on pulmonary vessels have been sufficiently de-
scribed by other groups and can explain our find-
ings [6, 7].
Most of our patients were on angiotensin re-
ceptor antagonist treatment. As we have been in-
formed by Koifman et al. [33], this, in combination
with arginine, serves to improve the flow mediated
vasodilatation decreasing afterload and increase ni-
tric oxide urinary excretion. These effects had been
observed even in cardiac transplant recipients [34].
Until now, when one spoke of HFpEF, it was
necessary to take into account that the values were
taken at rest. When patients with HFpEF were sub-
jected to stress (as we demonstrated with the ra-
dioisotopic ventriculography) [35], both ventricu-
lar ejection fractions tended to diminish, or at best
remain the same. This condition has a direct impact
on the functionality of the patients, leading to pro-
gressive decrease in their tolerance of daily activi-
ties. Thus, lowering systemic and pulmonary artery
pressure, by improving the afterload of both ven-
tricles, will lead to increased right ventricular ejec-
tion fraction. The greatest effect will be seen after
physical exertion and will be evident as a decrease
in right ventricular diastolic diameter. Even right
ventricular systolic function improved, it could in-
crease left ventricle end-diastolic-volume, but re-
duction of systemic blood pressure as was observed,
allows preserve the LVEF. Whether right ventri-
cular output increase results in pulmonary conges-
tion, it was not observed as could be demonstrated
with better exercise tolerance, probably as conse-
quence of a decrease in systemic systolic and dias-
tolic blood pressure.
It is also noteworthy that improvement in sys-
tolic arterial pressure and right ventricular function
was similar in both treatment groups, but L-citrulline
was better tolerated and required a lower dose. Con-
sequently, especially in HFpEF patients with PAH
and concomitant right ventricular failure, the use of
L-arginine or L-citrulline could be an adjunct to con-
ventional therapy. In addition, in patients with higher
right ventricular diastolic diameter and pulmonary
artery systolic pressure with smaller left chamber
diameters (left ventricular and atrial end-diastolic dia-
meters), it is frequent to find elevated troponin levels
that are associated with worse prognosis [36].
Finally, conventional heart failure treatment
was not different during the intervention, and the
observed changes should be explained by amino-
acids supplementation, although a control group was
not included.
This study has several limitations: the number
of patients studied was small, the intervention peri-
od was short and it is probable that a longer follow-
up would show changes in variables such as left ven-
tricular diastolic diameter and ejection fraction. Fi-
nally, the lack of direct quantification of pulmonary
pressures is a drawback. However, the findings of
this study support continued investigation into the
effect of L-arginine and L-citrulline on right ventric-
ular function, systemic arterial pressure and systol-
ic pulmonary artery pressure in heart failure patients
with preserved ejection fraction. More studies are
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required to evaluate the effects observed on a larg-
er number of patients for a longer period.
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